Nolpaza (Pantoprazole)

Pantoprazole, the active ingredient in Nolpaza, is a proton pump inhibitor presented as an intravenous solution for intravenous use. It treats acid‑related disorders such as gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease and helps prevent stress ulcers in critically ill patients.

GNH USA supplies Nolpaza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Our global network ensures reliable delivery and support for clinical use across diverse healthcare settings.

Pantoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal conditions.

- Gastro‑oesophageal reflux disease (GERD): reduces gastric acid exposure, relieving heartburn and esophageal irritation. - Erosive esophagitis: promotes healing of inflamed esophageal mucosa by suppressing acid secretion. - Peptic ulcer disease: facilitates ulcer healing and reduces risk of recurrence through sustained acid suppression. - Prevention of stress ulcers in critically ill patients: provides prophylactic acid control to lower the incidence of stress‑related gastric lesions.

Pantoprazole may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may be self‑limiting. - Nausea: transient feeling of queasiness. - Abdominal pain: discomfort in the upper abdomen. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis, angioedema): require immediate medical attention. - Clostridioides difficile‑associated diarrhea: can be life‑threatening and needs prompt treatment. - Electrolyte disturbances (hypomagnesemia, hypocalcemia): may cause muscle cramps or cardiac arrhythmias. - Hepatic enzyme elevation: indicates possible liver injury. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare but serious skin reactions.

When using Nolpaza, consider the following precautions to ensure safe therapy.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution; dose adjustment may be required. - Elderly patients: observe for electrolyte imbalances and renal function changes. - Concomitant antiplatelet therapy: increased risk of gastrointestinal bleeding; monitor closely. - Known hypersensitivity to pantoprazole or other PPIs: contraindicated. - Store at room temperature: keep in the original container, protect from light and moisture.

Pantoprazole can interact with several medicines; awareness of these interactions helps optimize patient outcomes.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic antiviral levels. - Methotrexate (high dose): increased serum concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent coagulation monitoring. - Digoxin: may raise digoxin levels; monitor for signs of toxicity. - HIV protease inhibitors (e.g., ritonavir): altered metabolism; adjust dosing as appropriate.